STAAR Surgical Stock Tumbles After Q2 Earnings: Here's Why
Portfolio Pulse from Vandana Singh
STAAR Surgical Company's Q2 sales reached $92.3 million, up 14% Y/Y, but missed the consensus of $93.04 million. The company reported Q2 adjusted EPS of $0.40, down from $0.42 a year ago, beating the consensus of $0.32. The company updated its fiscal 2023 ICL sales outlook to a range of approximately $320 million to $325 million, which is lower than the consensus of $346.46 million. The company's shares are down 11.5% at $46.27.
August 04, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
STAAR Surgical's Q2 sales and EPS beat expectations but the company lowered its 2023 sales outlook. The company's shares are down 11.5%.
STAAR Surgical's Q2 sales and EPS beat expectations, which is positive for the stock. However, the company lowered its 2023 sales outlook, which is negative for the stock. The stock price is down 11.5%, indicating that the market has reacted negatively to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100